XML 25 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Net sales $ 1,354.4 $ 1,243.4 $ 4,053.7 $ 3,743.6
Cost of sales 262.9 250.6 825.3 727.4
Gross profit 1,091.5 992.8 3,228.4 3,016.2
Selling, general, and administrative expenses 421.4 381.9 1,297.3 1,165.9
Research and development expenses 253.4 242.8 781.9 720.8
Intellectual property agreement and certain litigation expenses (Note 3) 10.8 2.2 27.8 193.6
Change in fair value of contingent consideration liabilities (Note 9) 0.0 0.0 0.0 (26.2)
Restructuring expenses (Note 4) 32.9 0.0 32.9 0.0
Other operating expenses, net 22.4 0.0 22.4 0.0
Operating income, net 350.6 365.9 1,066.1 962.1
Interest income, net (24.3) (15.1) (56.3) (32.8)
Other non-operating income, net (27.9) (6.6) (35.6) (10.3)
Income from continuing operations before provision for income taxes 402.8 387.6 1,158.0 1,005.2
Provision for income taxes 40.7 52.7 107.0 118.3
Net income from continuing operations 362.1 334.9 1,051.0 886.9
Income from discontinued operations, net of tax 2,707.3 48.8 2,734.4 142.8
Net income 3,069.4 383.7 3,785.4 1,029.7
Net loss attributable to noncontrolling interest (1.4) (1.2) (3.6) (2.8)
Net income attributable to Edwards Lifesciences Corporation $ 3,070.8 $ 384.9 $ 3,789.0 $ 1,032.5
Basic:        
Continuing operations (in dollars per share) $ 0.61 $ 0.55 $ 1.76 $ 1.47
Discontinued operations (in dollars per share) 4.53 0.08 4.55 0.23
Basic earnings per share (in dollars per share) 5.14 0.63 6.31 1.70
Diluted:        
Continuing operations (in dollars per share) 0.61 0.55 1.75 1.46
Discontinued operations (in dollars per share) 4.52 0.08 4.54 0.23
Diluted earnings per share (in dollars per share) $ 5.13 $ 0.63 $ 6.29 $ 1.69
Weighted-average number of common shares outstanding:        
Basic (in shares) 597.2 607.0 600.3 607.2
Diluted (in shares) 598.1 609.5 602.2 610.2